Safety and activity of DCR-MYC, a first-in-class Dicer-substrate small interfering RNA (DsiRNA) targeting MYC, in a phase I study in patients with advanced solid tumors.
The DOI matches its Crossref record.
Abstract
Article Tools Tumor Biology Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/jco.2015.33.15_suppl.11006 Journal of Clinical Oncology - published online before print May 20, 2015 Safety and activity of DCR-MYC, a first-in-class Dicer-substrate small interfering RNA (DsiRNA) targeting MYC, in a phase I study in patients with advanced solid tumors. Anthony W. TolcherxAnthony W. TolcherSearch for articles by this author , Kyriakos P. PapadopoulosxKyriakos P. PapadopoulosSearch for articles by this author , Amita PatnaikxAmita PatnaikSearch for articles by this author , Drew Warren RascoxDrew Warren RascoSearch for articles by this author , Dorothy MartinezxDorothy MartinezSearch for articles by this author , Debra L WoodxDebra L WoodSearch for articles by this author , Barbara FielmanxBarbara FielmanSearch for articles by this author , Manish SharmaxManish SharmaSearch for articles by this author , Linda A. JanischxLinda A. JanischSearch for articles by this author , Bob D BrownxBob D BrownSearch for articles by this author , Pankaj BhargavaxPankaj BhargavaSearch for articles by this author , Mark J. RatainxMark J. RatainSearch for articles by this author Show More START, San Antonio, TX; START Center for Cancer Care, San Antonio, TX; Nadler Pharma Associates, LLC, Randolph, NJ; Dicerna Pharmaceuticals, Cambridge, MA; The University of Chicago Medicine, Chicago, IL; University of Chicago, Chicago, IL; The University of Chicago, Chicago, IL Abstract Disclosures https://doi.org/10.1200/jco.2015.33.15_suppl.11006 Abstract Abstract 11006 Background: MYC, an oncoprotein deregulated in over half of all human malignancies, has thus far been considered "undruggable" with conventional approaches. RNA interference (RNAi), a therapeutic approach that can be used to silence the MYC oncogene, has been shown to inhibit cancer growth in animal models. Synthetic DsiRNA with specificity for MYC have demonstrated highly potent activity in vitro (picomolar IC50), and anti-MYC DsiRNA formulated in EnCore lipid nanoparticles (DCR-MYC) have demonstrated activity in vivo across various tumor models. DCR-MYC is the first MYC-targeting siRNA to enter clinical trials. Methods: This phase I, dose-escalation study (3+3 design) evaluated the safety, pharmacokinetics (PK), pharmacodynamics (PD) and clinical activity of DCR-MYC in patients (pts) with advanced solid tumors, multiple myeloma or lymphoma. DCR-MYC is administered as a 2-hr IV infusion on Day 1 and 8 of a 21 day cycle. Given the role of MYC in tumor metabolism, FDG-PET is obtained after cycle 1 to assess early metabolic response, while RECIST response is assessed after every 2 cycles. Results: Nineteen pts have been treated across 5 dose levels (0.1, 0.125, 0.156, 0.2, 0.3 mg/kg): 8M/11F, median age 58 yrs, ECOG PS 0(5), 1(14). Tumor types include NET (4), MBC (4), CRC (3), Ovarian (2), Appendiceal (2), other (4). The most common treatment-related AEs (all grades/grade 3) include fatigue (7/0), nausea (5/0) and infusion reactions (3/1). A pt with PNET treated at 0.1 mg/kg experienced DLT (transient grade 3 AST) and fatigue. This pt experienced a complete metabolic response (based on FDG-PET) after cycle 1 which has been sustained for > 8 months without further treatment. Metabolic responses after cycle 1, as well as evidence of tumor shrinkage have been observed in multiple patients. Preliminary PK analysis from the first two dose levels shows dose proportional changes in AUC and Cmax. Conclusions: DCR-MYC, a novel MYC inhibitor, is well tolerated and shows promising initial clinical and metabolic responses across various dose levels. These data support early validation of MYC as a therapeutic target. Updated results from the ongoing study will be presented. Clinical trial information: NCT02110563. © 2015 by American Society of Clinical Oncology
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Anselmo, A. C., & Mitragotri, S. (2016) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10003 · Cited by 1,321
The MYC oncogene — the grand orchestrator of cancer growth and immune evasion
Dhanasekaran, R., Deutzmann, A., Mahauad-Fernandez, W. D., Hansen, A. S., Gouw, A. M., & Felsher, D. W. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00549-2 · Cited by 986
Knocking down disease: a progress report on siRNA therapeutics
Wittrup, A., & Lieberman, J. (2015) · Nature Reviews Genetics · doi:10.1038/nrg3978 · Cited by 804
Thi, T. T. H., Suys, E. J. A., Lee, J. S., Nguyen, D. H., Park, K. D., & Truong, N. P. (2021) · Vaccines · doi:10.3390/vaccines9040359 · Cited by 525
Wolfram, J., & Ferrari, M. (2019) · Nano Today · doi:10.1016/j.nantod.2019.02.005 · Cited by 436
Metadata
- Authors
- Tolcher, A. W., Papadopoulos, K. P., Patnaik, A., Rasco, D. W., Martinez, D., Wood, D. L., Fielman, B., Sharma, M., Janisch, L. A., Brown, B. D., Bhargava, P., & Ratain, M. J.
- Venue
- Journal of Clinical Oncology
- Published
- 2015-05-20
- Volume
- 33
- Issue
- 15_suppl
- Pages
- 11006-11006
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2502048764
- Cited by
- 117
- References
- 0
- Type
- conference abstract
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Safety and activity of DCR-MYC, a first-in-class Dicer-substrate small interfering RNA (DsiRNA) targeting MYC, in a phase I study in patients with advanced solid tumors. https://app.cochat.ai/papers/10.1200/jco.2015.33.15_suppl.11006
- The paper
- Tolcher, A. W., Papadopoulos, K. P., Patnaik, A., Rasco, D. W., Martinez, D., Wood, D. L., Fielman, B., Sharma, M., Janisch, L. A., Brown, B. D., Bhargava, P., & Ratain, M. J. (2015). Safety and activity of DCR-MYC, a first-in-class Dicer-substrate small interfering RNA (DsiRNA) targeting MYC, in a phase I study in patients with advanced solid tumors. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2015.33.15_suppl.11006
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.